Clinical Cardiology: New Frontiers

Frontiers in Interventional Cardiology

Eric J. Topol, MD; Patrick W. Serruys, MD, PhD

In more than 20 years since the first percutaneous coronary revascularization procedures, the field of interventional cardiology has proliferated beyond all expectations. Now more than 1 million procedures are performed worldwide each year. Stenting has revolutionized the field, which previously relied on balloon dilatation in the majority of patients. With ≈50% of patients now undergoing stent implantation, the groundwork is laid for further important advances. In this article, we discuss the 4 most important new advances in the field of interventional cardiology: platelet inhibition, prevention of restenosis, stent evolution, and angiogenesis.

Platelets

Proximate Cause of Stent Thrombosis

Considerable progress in the field of percutaneous coronary revascularization has been made by appreciation of the pivotal role of platelets and the development of new therapies directed against platelet aggregation. The entire field of stenting was catapulted forward with the realization that subacute thrombosis was predominantly attributable to a platelet thrombus. Since the beginning of coronary stenting in 1986, thromboprophylaxis consisted of full doses of heparin and coumarin, along with aspirin and dipyridamole.1,2 This regimen resulted in the necessity for prolonged hospital stays to achieve therapeutic anticoagulation and in excessive bleeding complications and was still ineffective in preventing stent thrombosis in at least 4% to 5% of patients.2–6 The prevailing belief was that stent thrombosis, which occurred primarily several days after the index procedure, was due to a fibrin-rich (red) thrombus.7–9 Many of the cases of stent thrombosis were linked to suboptimal anticoagulation.8,9 The complication of stent thrombosis is dreaded, because it may result in myocardial infarction (MI) or death.8,9 The possibility that stent thrombosis was precipitated by inadequate expansion of the stent was explored independently of the search for a better pharmacological protective strategy.

Evidence for causal white thrombus came from platelet flow cytometry data, indicating the increased expression of the platelet glycoprotein IIb/IIIa receptor in patients who developed this complication of stenting.13 Rather than abnormalities in markers of coagulation activation, such as the cleaved fragment of prothrombin (F1.2) or thrombin-antithrombin complexes, a series of consecutive patients demonstrated that the dominant biochemical abnormality was related to platelet activation.

Angioscopic data from patients with subacute stent thrombosis showed white (platelet-rich) thrombus as the culprit,14 and reports of failure of plasminogen activators to achieve lysis of stent thrombosis15 corroborated the sense that the pathogenesis of this entity was largely attributable to platelet aggregation. Clinical trials were mounted to test the value of a platelet-directed strategy of aspirin and ticlopidine compared with the full anticoagulation approach of prolonged heparin and coumarin.16,17 Furthermore, trials compared aspirin as a sole antiplatelet agent with the combination of aspirin and the ADP receptor antagonist ticlopidine.17–20 These trials are summarized in Table 1. The benefit of an antiplatelet approach over the traditional strategy was striking, as first shown in the Munich Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial and later confirmed in the Stent Anticoagulation Regimen Study (STARS) trial.16,17 These findings, coupled with the benefit of an intensified dual antiplatelet inhibitor approach as opposed to aspirin alone,17–20 provide a very strong foundation for platelet thrombus to be regarded as the principal pathogenic factor in stent thrombosis. The incidence of subacute stent thrombosis is now regarded as <1% to 2%. Accounting for this are the 2 cardinal changes in approach: more optimal deployment by use of higher balloon dilatation pressures, and combination antiplatelet therapy with aspirin and ticlopidine. The marked reduction in the incidence of stent thrombosis and the simplification of the pharmacological regimen has greatly reduced the cost of stenting by making overnight hospital stays routine, along with the possibility of transforming stent deployment to an outpatient procedure in select patients.21

Recently, ticlopidine has been associated with thrombocytopenic thrombotic purpura.22,23 A new ADP receptor antagonist, clopidogrel, has thus far not been shown to induce this serious microangiopathic disorder or been implicated in bone marrow toxicity. Clopidogrel is currently being assessed in coronary stent trials for comparative efficacy and safety compared with ticlopidine.

Development of IIb/IIIa Inhibitors

Parallel to the improvement in pharmacological coverage to protect against stent thrombosis, a new class of drugs was being explored for balloon PTCA. For several years, it had been known that a final common pathway for platelet aggregation existed. Elucidation of the biology of this glycoprotein IIb/IIIa receptor, the most densely expressed adhesion molecule on the platelet surface, laid the groundwork for...
TABLE 1. Stent Randomized Thromboprophylaxis Trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>n</th>
<th>ASA + Ticlid</th>
<th>ASA only</th>
<th>ASA + Coumarin</th>
<th>Composite Event Rates (Death, MI, Revascularization), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hall et al18</td>
<td>226</td>
<td>0.8</td>
<td>3.9</td>
<td>...</td>
<td>27.6</td>
</tr>
<tr>
<td>ISAR19</td>
<td>517</td>
<td>1.6</td>
<td>...</td>
<td>6.2</td>
<td>27.6</td>
</tr>
<tr>
<td>FANTASTIC20</td>
<td>485</td>
<td>5.7</td>
<td>...</td>
<td>8.6</td>
<td>27.6</td>
</tr>
<tr>
<td>STARS21</td>
<td>1652</td>
<td>0.6</td>
<td>3.6</td>
<td>2.4</td>
<td>27.6</td>
</tr>
<tr>
<td>MATTIS22</td>
<td>350</td>
<td>5.6</td>
<td>...</td>
<td>11.0</td>
<td>27.6</td>
</tr>
</tbody>
</table>

ASA indicates aspirin; ISAR, Intracoronary Stenting and Antithrombotic Regimen trial; FANTASTIC, Full ANTicoagulation versus Ticlopidine and Aspirin after STent Implantation: a randomized multiCenter European study; STARS, Stent Anticoagulation Regimen Study; and MATTIS, Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting in high-risk patients.

Coller24 to develop a monoclonal antibody.25 The antibody was the first agent to enter clinical trials, later followed by a peptide and several small-molecule competitive inhibitors of this adhesion molecule receptor.

Six large placebo-controlled, double-blind trials were undertaken to test IIb/IIIa antagonists in patients undergoing PTCA, as summarized in Table 2.26–31 The Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications (EPIC) trial26 was the first "proof of concept" and demonstrated a marked, 36% reduction in the incidence of death or MI within 30 days of the procedure (Figure 1). This trial was conducted in high-risk patients, eligible because of an acute coronary syndrome or known angiographic liabilities for acute complications.27 Either PTCA or directional atherectomy was the revascularization procedure. Of note, only the bolus and sustained infusion (>12 hours) but not the bolus per se strategy was effective in reducing adverse outcomes. This strongly suggested that the duration of IIb/IIIa blockade would play out as an important modulator of therapeutic potential.

The subsequent 5 trials confirmed and extended the EPIC findings in many ways.27–31 First, each trial showed benefit of IIb/IIIa inhibition (Figure 1), with reduction of major adverse events. Second, the field of patients was expanded to include any routine percutaneous intervention rather than only a high-risk inclusion criterion. Third, the bleeding complications encountered in EPIC were related to excessive heparin and prolonged indwelling vascular sheath time. In the trials that followed, using lower doses of weight-adjusted heparin and reducing the time of vascular sheaths, the initial doubling of bleeding in the patients receiving IIb/IIIa was reduced to levels similar to those in the control group.30

Stents and IIb/IIIa Inhibitors

By virtue of the benefit of 2 different and distinct mechanisms, the concept of using both arterial scaffolding and protection from platelet thrombosis represents an attractive clinical strategy. Supportive data for this combination in patients receiving stents were demonstrated in subgroups of randomized trials.32,33 As shown in Figure 2, in the Evaluation of PTCA to Improve Long-term Outcome by c7E3 GPIIb/IIIa Receptor Blockade (EPILOG) trial, >300 patients underwent stenting because of suboptimal balloon angioplasty results, and the benefit for IIb/IIIa inhibition with respect to reduction of MI and emergency revascularization was striking.32 Of note, the favorable effects for combined IIb/IIIa inhibition

TABLE 2. Principal Features of the 6 Large Trials of IIb/IIIa Inhibitors in Interventional Cardiology

<table>
<thead>
<tr>
<th>Trial</th>
<th>n</th>
<th>Drug</th>
<th>Patients</th>
<th>Heparin</th>
<th>Sheath Time, h</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIC</td>
<td>2099</td>
<td>Abciximab</td>
<td>High-risk</td>
<td>Full</td>
<td>&gt;24</td>
</tr>
<tr>
<td>IMPACT</td>
<td>4010</td>
<td>Eptifibatide</td>
<td>No restriction*</td>
<td>100 U/kg, weight adjusted</td>
<td>~6</td>
</tr>
<tr>
<td>RESTORE</td>
<td>2139</td>
<td>Tirosiban</td>
<td>Unstable angina, acute MI</td>
<td>Full</td>
<td>~6</td>
</tr>
<tr>
<td>CAPTURE</td>
<td>1265</td>
<td>Abciximab</td>
<td>Unstable angina</td>
<td>Full</td>
<td>&gt;24</td>
</tr>
<tr>
<td>EPILOG</td>
<td>2792</td>
<td>Abciximab</td>
<td>No restriction*</td>
<td>70 or 100 U/kg, weight adjusted</td>
<td>&lt;6</td>
</tr>
<tr>
<td>EPISTENT</td>
<td>2399</td>
<td>Abciximab</td>
<td>No restriction*</td>
<td>70 or 100 U/kg, weight adjusted</td>
<td>&lt;6</td>
</tr>
</tbody>
</table>

EPIC indicates Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications; IMPACT, Integrilin to Manage Platelet Aggregation to prevent Coronary Thrombosis; RESTORE, Randomized Efficacy Study of Tirosiban for Outcomes and Restenosis; CAPTURE, Chimeric 7E3 Anti-platelet in Unstable angina Refractory to standard treatment; EPILOG, Evaluation of PTCA to Improve Long-term Outcome by c7E3 GPIIb/IIIa receptor blockade; and EPISTENT, Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

*No restriction refers to enrollment of all patients suitable for percutaneous intervention using a Food and Drug Administration–approved device. Rotablation as a planned revascularization was not an entry criterion in EPILOG.
(administered on a prophylactic basis) and stenting had thus far been shown only in patients with poor or suboptimal initial results. A dedicated trial (known as Evaluation of Platelet IIb/IIIa Inhibitor for Stenting [EPISTENT]) studied the use of IIb/IIIa blockade with elective stenting. In this trial, balloon angioplasty and abciximab was compared with either stenting and placebo or stenting and abciximab in a total of 2399 patients. For the combination of stenting and abciximab, compared with stenting and placebo, a striking (50%) reduction of death and MI at 30 days and 6 months was demonstrated. The balloon-abciximab arm also was significantly improved compared with stenting and placebo. These findings accentuate the need for improved antiplatelet therapy with percutaneous intervention, whether it be with stenting or balloon angioplasty.

The IIb/IIIa trials in interventional cardiology, interestingly, have consistently reduced the need for emergency or “bailout” stenting (Figure 3). Each trial that was performed in an era where stents were available showed a lesser need, with an overall 24% reduction. All of these trials were performed in a double-blind fashion. This, along with the consistent findings across trials and the magnitude of the reduction, bespeaks a prominent effect of improved antiplatelet coverage for achieving better results in percutaneous intervention without stenting. Whether indeed stenting should be avoided when possible or actually applied more frequently is an unsettled issue. Notwithstanding the provisional stent debate, the interaction of stenting and antiplatelet therapy is clearly a critical one for future optimization of patient outcomes.

### Restenosis
Initially, it was thought that IIb/IIIa blockade might have a salutary effect on clinical restenosis. This was based on the long-term effects of the original EPIC trial, in which there was a 24% reduction of target-vessel revascularization at 6 months in the abciximab bolus and infusion treatment group. Furthermore, this benefit was sustained even at 3 years of follow-up. Theoretically, this occurred on the basis of potent platelet inhibition before and for the first few days after the arterial dilatation. By attenuation of the platelet-aggregation response, less growth factor (such as platelet-derived growth factor) and vasoactive amine (eg, serotonin, thromboxane A2) would be released. In addition, abciximab is known to inhibit the vitronectin receptor, an integrin with homology to IIb/IIIa because of the shared β-3 subunit and 70% of the α-subunit. Because abciximab cross-reacts fully with the vitronectin receptor and is a critical pathway for governing smooth muscle cell migration, theoretically a dual approach of platelet and smooth muscle cell antagonism was operational. However, when the same IIb/IIIa inhibitor was used in the subsequent EPILOG trial, there was no 6-month effect on target-vessel revascularization. This was also the case in both the ERASER and RAPPORT trials, as summarized in Table 3.

As shown in Figure 4, however, there was a pronounced change in the need for target-vessel revascularization from the initial to the more contemporary abciximab trial. This reduction in the placebo group of the respective trials is quite impressive and probably reflects the era of more aggressive dilatation that has characterized percutaneous intervention since backup stenting was widely available in 1995. More recently, however, data from the EPISTENT 6 month follow-up results have become available. An overall 18% reduction in the need for repeat target vessel revascularization was demonstrated for abciximab compared with placebo in stent assigned patients (from 10.6% to 8.7%) with 50% reduction in diabetic patients (16.6% vs 8.1%, P = 0.02). Thus, in-stent restenosis, especially in diabetics, is favorably influenced by abciximab.

### Periprocedural MI
Since the first randomized trial of directional atherectomy versus balloon angioplasty, debate has arisen as to the significance of periprocedural non–Q-wave MI, which clearly occurs more frequently than expected. In aggregate, a number of studies with ample follow-up have shown that patients with a periprocedural MI characterized by a 3-fold elevation of total creatine kinase (CK), positive for myocardial band (MB), have a compromised long-term prognosis. The pa-
patients most apt to have a periprocedural non–Q-wave MI are those with diffuse atherosclerotic involvement, with long lesions or saphenous vein graft target stenoses, along with procedures that induce a deeper level of arterial injury, particularly atherectomy.44,45 Common to these higher-risk subsets is the responsiveness of IIb/IIIa inhibitors for the reduction of periprocedural MI. Although the predominant therapeutic effect of the IIb/IIIa inhibitors is in large MIs, Q-wave or non–Q-wave, there is clear-cut reduction of periprocedural MIs in the range of 3- to 5-fold CK elevation.26–31 Accordingly, using this drug class as a mechanistic probe, we know that at least some of these events are attributable to platelet aggregation, whether it be the site of arterial dilatation or in the microcirculation. The weight of evidence suggests that the chief hazard of periprocedural MI is increased death rate during extended follow-up,43 which appears to be directly related to the size of the MI. This may explain the favorable impact of IIb/IIIa blockade on mortality during extended follow-up,35 which appears to be directly related to the size of the MI. This may explain the favorable impact of IIb/IIIa blockade on mortality during extended follow-up of a cohort of patients with acute coronary syndromes in the initial EPIC trial.37 Nevertheless, periprocedural MIs still occur despite full doses of IIb/IIIa inhibitors, so that other factors, such as side-branch closure, atherosclerotic emboli, and overriding intimal disruption, play a role in some patients.

**TABLE 3. Major 6-Month End Points of the 5 Trials of IIb/IIIa Blockade in Interventional Cardiology**

<table>
<thead>
<tr>
<th>Trial</th>
<th>n</th>
<th>Placebo</th>
<th>Drug</th>
<th>Placebo</th>
<th>Drug</th>
<th>Placebo</th>
<th>Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPIC</td>
<td>2099</td>
<td>12.8</td>
<td>8.8</td>
<td>35.1</td>
<td>27.0</td>
<td>22.3</td>
<td>16.5*</td>
</tr>
<tr>
<td>IMPACT</td>
<td>4010</td>
<td>11.6</td>
<td>10.3</td>
<td>31.5</td>
<td>30.1</td>
<td>20.7</td>
<td>20.9</td>
</tr>
<tr>
<td>RESTORE</td>
<td>2139</td>
<td>8.6</td>
<td>7.8</td>
<td>27.1</td>
<td>24.1</td>
<td>17.1</td>
<td>15.7</td>
</tr>
<tr>
<td>CAPTURE</td>
<td>1265</td>
<td>10.9</td>
<td>9.0</td>
<td>31.6</td>
<td>31.4</td>
<td>25.9</td>
<td>25.8</td>
</tr>
<tr>
<td>EPILOG</td>
<td>2792</td>
<td>11.1</td>
<td>6.0</td>
<td>25.8</td>
<td>22.5</td>
<td>18.1</td>
<td>16.6</td>
</tr>
<tr>
<td>Pooled</td>
<td>12 305</td>
<td>10.9</td>
<td>8.5</td>
<td>29.8</td>
<td>26.9</td>
<td>20.2</td>
<td>18.6</td>
</tr>
</tbody>
</table>

TVR indicates target vessel revascularization; EPIC, Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications; IMPACT, Integrelin to Manage Platelet Aggregation to prevent Coronary Thrombosis; RESTORE, Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis; CAPTURE, Chimeric 7E3 Anti-platelet in Unstable angina Refractory to standard treatment; and EPILOG, Evaluation of PTCA to Improve Long-term Outcome by c7E3 GPIIb/IIIa receptor blockade.

**Use in Acute MI**

One of the most exciting frontiers in cardiovascular medicine is the ability to disaggregate platelets in the setting of acute MI.46 The underlying pathophysiology has been further elucidated, with the white clot central to the response to plaque fissure or erosion and the attendant exposure of subendothelial matrix. Until recently, there was no tool in our therapeutic armamentarium to dissolve the platelet clot—that is, to achieve “platelet lysis.” Indeed, the prothrombotic effects of plasminogen activators led to failure of angioplasty in the early randomized trials.46–49 This has been completely turned around by exploiting our newfound ability to dissolve white clot in the acute setting, with or without fibrinolytic therapy. Use of IIb/IIIa inhibition alone has resulted in infarct vessel patency rates approximating the use of streptokinase therapy.50

In the recently completed RAPPORT trial,41 of 483 patients undergoing PTCA for acute MI, the IIb/IIIa inhibitor group had a >40% reduction in death, MI, or urgent revascularization at 30 days (Figure 5). Neumann and colleagues,51 from Munich, Germany, reported a trial of 200 patients undergoing primary stenting for acute MI with a similar reduction of adverse outcomes with abciximab compared with conventional pharmacological therapy. Recent data from dose-finding trials in the TIMI-14 and GUSTO-4 trials indicate

**Figure 4.** Proportion of patients requiring repeat target-vessel revascularization in control groups of EPIC trial (conducted in 1992; control group, n=639) vs EPILOG trial (conducted primarily in 1995; control group, n=939) shows marked reduction in more contemporary trial (TVR required in 22.3% in EPIC, 16.6% in EPILOG).

**Figure 5.** RAPPORT trial event rates of death, MI, and urgent revascularization for abciximab vs placebo.
that half-dosing of tissue plasminogen activator (alteplase) or recombinant tissue plasminogen activator (reteplase), respectively, given in combination with full-dose abciximab, can achieve infarct vessel patency in >90% of patients by 60 to 90 minutes into therapy. In the related trials of acute coronary syndromes, the patients receiving IIb/IIIa blockers on presentation who had subsequent percutaneous coronary intervention during drug infusion derived the most benefit of all of the subgroups analyzed (Table 4).

It is thus likely that a pivotal component of future management of MI patients will involve more potent antplatelet therapy. The long-standing debate as to whether to perform catheter-based reperfusion or use pharmacological therapy could be preempted by a pharmacological strategy that markedly facilitates (rather than compromises) acute-phase intervention. Because one of the most important features of acute intervention is the “door-to-balloon” time, the use of a platelet-lysis approach to restore coronary blood flow while the patient is being transported to cardiac catheterization has important infarct-size limitation and practical appeal. Furthermore, the enhanced stability of the infarct vessel that has been passivated by the use IIb/IIIa blockade opens the potential for consideration of very early hospital discharge. Thus, IIb/IIIa blockade has set the stage for a veritable revolution in our care of the patient with acute MI eligible for reperfusion therapy.

Antirestenosis Strategies

The focus of the treatment of restenosis over the last 2 decades has been through the application of pharmacological agents and mechanical approaches using a host of different devices. Unfortunately, this frequent and costly complication of percutaneous revascularization techniques has proved refractory to all such therapies. The restenosis process is characterized by neointimal proliferation, which involves the migration of vascular smooth muscle cells from the media to the intima and their subsequent proliferation. The inciting stimuli involved in restenosis include disruption of the endothelial barrier layer, mechanical factors that disrupt the medial smooth muscle layer and serve as stimuli for smooth muscle cell proliferation and migration, and the contact of this disrupted layer with circulating blood factors and mitogens that serve as further stimuli to neointimal formation. Vascular injury sets into motion a cascade of events that results in the final hyperplastic response shown by the neointima. Early in our understanding of the pathophysiological processes involved in restenosis, attention was concentrated on factors that interact with smooth muscle cells through cell surface receptors. These include such compounds as thrombin, platelet-derived growth factor, angiotensin II, interleukin 1, insulin growth factor-I, basic fibroblast growth factor, and a whole host of other mitogenic factors. Initial treatments for restenosis targeted these receptors with pharmacological agents in an attempt to inhibit their effects. It soon became apparent, however, that none of these stimuli work through a unique or final common pathway. Instead, these signals interact at an intracellular level through redundant second-messenger systems, which confers redundancy to the system. Ultimately, these second-messenger systems converge on a final common pathway at the cellular DNA level known as the cell cycle.

The life cycle of a normal cell can be considered in 5 different cell phases. G0 (G = gap) is the quiescent state in which the cell is biologically active but is neither actively dividing or replicating. Under appropriate stimuli, the cell can then enter the G1 or interphase, in which biosynthetic activities of the cell prepare it to enter into the next phase of the cell cycle, or S phase. The S phase begins when DNA synthesis starts and ends when the DNA content of the nucleus has doubled and the chromosomes have replicated. The S phase is followed by G2, which ends when mitosis starts, signaling the start of the M phase. Activation of the cell cycle is responsible for both normal physiological growth and cell division, as well as for pathophysiological processes such as restenosis.

A large number of genes are involved in the control of cell cycle progression in eukaryotic cells. They can be divided into early G1 genes (such as c-fos, c-myc, etc), late G1 genes (c-myb, Rb, etc), genes involved in G1/S transition (edc1/edk kinases, etc), S-phase genes involved in DNA synthesis (DNA polymerases, proliferating cell nuclear antigen, etc), genes involved in G2/M transition (edc1/edk kinases, etc), and genes involved in mitosis (cytoskeletal proteins, mitosis-specific kinases, etc). In theory, suppression of any 1 of these genes will lead to interruption of cell cycle progression, a strategy that is being explored for the prevention of restenosis as we approach the new millennium. Two different tactics are currently being tested. Brachytherapy bombards the nuclear material with ionizing radiation, disrupting the templates for the production of cell cycle regulatory proteins. With the correct radiation dose, the target smooth muscle cell remains.

<table>
<thead>
<tr>
<th>PurSuit</th>
<th>Platelet IIb /IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network; PRISM Plus, Platelet Receptor Inhibition for Ischemic Syndrome Management study; and PARAGON A, Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network.</th>
</tr>
</thead>
<tbody>
<tr>
<td>PARAGON A</td>
<td>79.0</td>
</tr>
<tr>
<td>PRISM Plus</td>
<td>89.7</td>
</tr>
<tr>
<td>PURSUIT 79.0</td>
<td>34.0</td>
</tr>
<tr>
<td>PURSUIT</td>
<td>89.7</td>
</tr>
</tbody>
</table>

Table 4. Use of Percutaneous Coronary Revascularization While on IIb/IIIa Blockade Therapy in 3 Trials of Empirical Therapy in Acute Coronary Syndromes
viable but unable to replicate. The other approach depends on a biological attack on the cell regulatory machinery using gene therapy technology for the introduction of foreign fragment nuclear material to halt the pathophysiological processes typical of restenosis.

A number of different approaches using the basic techniques of gene therapy are currently being tested for the prevention of neointimal hyperplasia. The most straightforward involve the transfer of a gene directly into the proliferating smooth muscle cells. This gene can encode for a cytotoxic protein (eg, herpes virus thymidine kinase), a cell cycle–inhibitory protein (eg, p53, p21, Rb, cdk), angiogenic proteins (eg, vascular endothelial growth factor [VEGF], angiogenin, basic fibroblast growth factor), or proteins with vasodilatory, antithrombotic, or antiproliferative properties (eg, nitric oxide synthase, cox-1, plasminogen activator inhibitor type 1). This kind of approach has been shown to be effective in several animal models of restenosis. With adenovirus used as a vector, herpes virus thymidine kinase has been successfully transfected into vascular smooth muscle cells at the site of balloon injury in the femoral arteries of swine. This was followed by systemic administration of the nucleoside analogue ganciclovir, which in the presence of the foreign thymidine kinase can be incorporated into the cellular DNA. With this technique, both smooth muscle cell proliferation and luminal narrowing were shown to be inhibited. Adenovirus-mediated transfer of the retinoblastoma (Rb) gene, whose protein product inhibits cell cycle progression, has also been shown to be successful in a similar animal model. Transfer of the gene coding for nitric oxide synthase using both a protein/liposome hybrid vector and an adenovirus vector, as well as of angiotensin II type 2 receptor and the thrombin inhibitor hirudin using adenovirus vectors, has also been shown to be effective for the prevention of restenosis in the rat carotid model of vessel injury.

Other targets being investigated for the prevention of restenosis are the matrix metalloproteinases (MMPs). Smooth muscle cell migration and proliferation are normally hindered by the inhibitory constraints of the extracellular matrix. Matrix remodeling by matrix-degrading metalloproteinases is therefore essential for smooth muscle proliferation and migration into the intima. Synthetic inhibitors of MMPs have been shown to inhibit smooth muscle migration and proliferation in several in vitro systems. There are several naturally occurring tissue inhibitors of metalloproteinases (TIMPs) that can inhibit their activity. To date, 3 TIMPs have been well characterized (TIMP-1, -2, and -3), and a fourth has been cloned. The identification of these inhibitors has led to the idea that overexpression of TIMPs may have potential as a gene therapy approach for the prevention of neointimal formation. Support for TIMP gene therapy comes from recent work by George and colleagues at the Bristol Heart Institute. In human saphenous vein in tissue culture, these investigators were able to demonstrate that highly localized overexpression of TIMP-1 after recombinant adenovirus-mediated transfection markedly inhibited neointimal formation. These results not only provide proof of principle for ex vivo gene therapy with TIMP-1 for the reduction of neointimal formation in vein grafts but also suggest an in vivo application at the time of intervention for the prevention of coronary artery restenosis.

Another “nuclear weapon” being developed for the prevention of restenosis involves antisense oligonucleotide technology. Antisense oligodeoxynucleotides are short pieces of DNA with sequences that are complementary to specific regions of messenger RNA. The major mechanisms of action of these compounds are through the sequence-specific interaction with messenger RNA, although sequence-specific and sequence-nonspecific effects have also been demonstrated. On binding to the target, the antisense compound sterically inhibits the interaction of ribosomes with the messenger RNA. Another mechanism of action, which may be as important as the steric inhibition of ribosome binding, is a consequence of the DNA/RNA hybrid being more susceptible to degradation by intracellular RNase than single-stranded messenger RNA. This results in an increased clearance of target mRNA from the cell. In principle, any gene may be selected for antisense suppression; inhibition of certain genes will certainly be more biologically effective. Important in this regard are the abundance of the messenger RNA, the half-life of the protein product, and the existence of redundancy within the cell such that other proteins are capable of performing functions similar to that which is targeted. Given these considerations, it is not surprising that most of the attention of antisense technology has been focused on the short-lived regulators of the final common pathway of mitogenic stimuli, the cell cycle. Inhibition of the production of several of the mediators of the cell cycle with antisense oligonucleotides has been shown to be effective for the prevention of restenosis in several different animal models of vascular injury (Table 5). The results of a single-center clinical trial performed in Rotterdam that examined the effectiveness of antisense compound directed against messenger RNA for the protein product of the c-myc gene will soon be reported. This will be the first human trial to use an antisense DNA strategy for the prevention of restenosis.

With our increased understanding of vascular molecular biology, more sophisticated approaches that use the basics of gene therapy are being investigated. For instance, cell-based vascular gene-delivery techniques are now being explored as means to provide biologically relevant amounts of therapeutic agents to the site of vessel damage. This strategy involves the isolation of autologous endothelial or smooth muscle cells, ex vivo gene transfer, followed by the reintroduction of the genetically modified cells back to the region selected for therapy. The disadvantages of this approach include the requirement to isolate and modify cells from each patient, with the consequent delay in therapy, and the failure to date, with few exceptions, to show a relevant expression of recombinant protein in vivo. To circumvent these problems, the laboratory of one of the authors (P.W.S.) is focusing on the xenotransplantation of genetically modified endothelial cells for the prevention of restenosis. For this purpose, animals have been engineered that are doubly transgenic in that they carry not only a human gene that can produce an agent for the prevention of restenosis but also gene coding for human cell surface markers so that they may be effectively xenotransplanted into humans and therefore provide a local
source of bioactive compounds. These animals provide a limitless supply of endothelial cells producing controllable levels of active compound, which can be used for xenotransplantation at the site of vessel injury in humans. These foreign cells act as a kind of Trojan horse, graciously accepted as self by the host organism but capable of modifying the pathophysiological response to vessel damage typified by the process of restenosis. Once implanted, the production of the bioactive compound is under exogenous control by means of “designer” genes coding for modified cell-surface receptors that are introduced. In this system, interaction of an orally administered compound with the modified cell receptor can switch on the transgene, whereas in its absence the transgene remains dormant. The feasibility of this type of approach has been demonstrated in other animal species, and it shows great potential for application to humans. The applicability of this type of therapeutic delivery system to other pathophysiological conditions and the shortage of tissue for organ transplantation are the fuel for continued high research activity in this direction.

As our understanding of the molecular control of cellular function increases and our knowledge of the pathophysiology of restenosis expands, new types of gene therapy approaches will be developed for the treatment of this iatrogenic complication. An area of active investigation is the development of new techniques for the introduction of foreign DNA into whole cells. All of the currently available viral and nonviral vectors have significant limitations to their use. The introduction of an effective, nonimmunogenic delivery vehicle is on the horizon. As the last decade was the era of mechanical and pharmacological approaches to the prevention of restenosis, developments in the coming decade will be aimed at manipulating the genetic material of the proliferating cell.

Stents
The use of coronary stent implantation as a primary treatment modality in interventional cardiology has increased at a staggering rate. In most interventional centers, stents are used in ≥50% of all coronary angioplasty procedures. This “stenotomania” is driven both by the gratifying short-term results seen by the interventionalist using these devices and by results extrapolated from observational and randomized trials. The “bigger is better” dogma first proposed by Kuntz and his colleagues has been adopted by many operators, who feel that the greater the acute gain in lumen diameter, the smaller the chances of short- and long-term failure. Inherent in this concept is the stent is merely a means to an end, and therefore, irrespective of the particular stent or other dilating or debulking device used, success of the procedure is determined solely by the acute results. Whether differences between various stent designs and materials are sufficient to impact their clinical effects remains to be demonstrated in controlled “stent versus stent” trials. The positive results of the few completed randomized trials have been enthusiastically applied to almost every other patient and lesion subcategory. The unequivocal indications for stenting are currently only those few that have been supported by observational and randomized trials and are limited to very few stent types. The definitive evidence for the use of stents for several specific clinical indications is still lacking. As results of the many ongoing randomized stent trials become available, the indications for stenting will have to be adapted accordingly. Currently, there is solid evidence from observational studies and randomized trials to support the use of coronary stents for the following indications: (1) treatment of abrupt or threatened vessel closure during angioplasty, (2) primary reduction in restenosis in de novo focal lesions in vessels >3.0 mm in diameter, (3) focal lesions in saphenous vein grafts, (4) totally occluded vessels, and (5) treatment of acute MI.

**Are They All Equivalent?**
With the current and future plethora of intracoronary stenting devices, the obvious question that must be answered is whether the choice of a particular stent makes a difference with respect to clinical outcome. Two lines of evidence, 1 experimental and the other clinical, suggest that a difference

### TABLE 5. In Vivo Antisense Studies

<table>
<thead>
<tr>
<th>Investigators</th>
<th>Experimental Model</th>
<th>Gene</th>
<th>Delivery Vehicle</th>
<th>% Intimal Suppression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simons et al</td>
<td>Rat</td>
<td>c-myb</td>
<td>Pluronic gel</td>
<td>84</td>
</tr>
<tr>
<td>Edelman et al</td>
<td>Rat</td>
<td>c-myb</td>
<td>EVav</td>
<td>80</td>
</tr>
<tr>
<td>Azrin et al</td>
<td>Pig</td>
<td>c-myb</td>
<td>Hydrogel catheter</td>
<td>NR</td>
</tr>
<tr>
<td>Gunn et al</td>
<td>Pig</td>
<td>c-myb</td>
<td>None</td>
<td>65</td>
</tr>
<tr>
<td>Bennet et al</td>
<td>Rat</td>
<td>c-myb</td>
<td>Pluronic gel</td>
<td>53</td>
</tr>
<tr>
<td>Edelman et al</td>
<td>Rat</td>
<td>c-myb</td>
<td>EVac</td>
<td>90</td>
</tr>
<tr>
<td>Shi et al</td>
<td>Pig</td>
<td>c-myb</td>
<td>None</td>
<td>70</td>
</tr>
<tr>
<td>Morishita et al</td>
<td>Rat</td>
<td>cdc-2/PCNA</td>
<td>HVJ</td>
<td>68</td>
</tr>
<tr>
<td>Abe et al</td>
<td>Rat</td>
<td>cdc-2</td>
<td>Pluronic gel</td>
<td>47</td>
</tr>
<tr>
<td>Abe et al</td>
<td>Rat</td>
<td>cdk-2</td>
<td>Pluronic gel</td>
<td>55</td>
</tr>
<tr>
<td>Morishita et al</td>
<td>Rat</td>
<td>cdk-2</td>
<td>HVJ</td>
<td>40</td>
</tr>
<tr>
<td>Simons et al</td>
<td>Rat</td>
<td>PCNA</td>
<td>Pluronic gel</td>
<td>80</td>
</tr>
<tr>
<td>Siros et al</td>
<td>Rat</td>
<td>PDGD-β receptor</td>
<td>EVac</td>
<td>70</td>
</tr>
</tbody>
</table>

EVac indicates ethylenevinylacetate; HVJ, hemagglutinating virus of Japan; and NR, not reported.
does indeed exist between different stents. In an animal model, it has been suggested that stent surface material and geometric configuration may be more important than operator-dependent variables in determining the degree of neointimal hyperplasia and thrombosis. Design characteristics such as hoop strength and metallic surface area have been shown to influence neointimal formation in experimental models. The metal composition and characteristics of the stent surface may also be important for the performance of the implanted stent.

Another factor that must be considered when assessing stent design is the mode of delivery: self-expanding versus balloon-expandable. The currently available self-expanding stents are configured as a slotted tube (Radius) or as a wire mesh (Wallstent) and are composed of either nitinol (Radius) or stainless steel (Wallstent). Although different in configuration and metal composition, they have in common a particular advantages and disadvantages of the 2 different modes of delivery.

To resolve the issue of whether stent configuration plays a major role in determining long-term outcome, large randomized trials are currently under way comparing various stent designs “head to head.” The equivalency design of these trials in simple ACSSTENT study (BENESTENT)-like lesions is predicated on showing similarity in safety and efficacy between the test stent and the Palmaz-Schatz stent, which serves as the standard with which all others are compared. These trials were not designed to test for subtle and perhaps clinically unimportant differences between stent designs, because an unnaturally large sample size would be required. Three trials have been completed. In all of these, stents were implanted in noncomplex lesions with a length of <25 mm in native coronary vessels. In addition to clinical end points, angiography was obtained in a subset of the patients, and all trials were powered to detect a 0.2-mm difference in minimal luminal diameter at 6 to 9 months after stent implantation by quantitative coronary arteriography. The ACS stENT Clinical Equivalence in de Novo Lesions (ACSENT) trial included 1040 patients randomized to either Palmaz-Schatz or Multi-Link stent implantation. Statistical equivalence in both the late clinical and angiographic (Table 6) outcomes were demonstrated for the Multi-Link and the Palmaz-Schatz stents. Likewise, clinical and angiographic (Table 6) equivalence between the Palmaz-Schatz stent and the Micro Stent II was shown in the Study of AVE-Micro Stent Ability to Limit Restenosis (SMART) trial, in which 613 patients with focal de novo or restenotic native coronary lesions were randomized. Equivalence between the GR II and the Palmaz-Schatz stent was not demonstrated in the GR II trial. Differences at 6-month follow-up were seen in the 6-month clinical outcomes of target-vessel revascularization and target-vessel failure (composite of death, MI, and target-vessel revascularization) (Figure 6). Significant differences were also seen in the 6-month follow-up angiographic parameters of minimal luminal diameter, percent diameter stenosis, and binary restenosis rate (Table 6). The reasons for these differences are not clear but may be due in part to a higher acute residual stenosis after stent implantation, a higher loss index in the GR II–treated vessels (0.76 versus 0.57; \( P=0.007 \)), or as a result of GR II stent undersizing or longer stent length in the GR II group. With the large number of stents currently available, it is questionable what practical purpose will be served by comparing all the available stents with the “standard” (Palmaz-Schatz) or with each other.

### TABLE 6. Angiographic Follow-Up of Stent Versus Stent Trials

<table>
<thead>
<tr>
<th>ACCENT</th>
<th>SMART</th>
<th>GR II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmaz-Schatz</td>
<td>Multi-Link</td>
<td>Palmaz-Schatz</td>
</tr>
<tr>
<td>No. of patients</td>
<td>520</td>
<td>520</td>
</tr>
<tr>
<td>ACC B2/C (%)</td>
<td>60§</td>
<td>63§</td>
</tr>
<tr>
<td>LAD (%)</td>
<td>43</td>
<td>43</td>
</tr>
<tr>
<td>Reference diameter (mm)</td>
<td>2.97</td>
<td>2.95</td>
</tr>
<tr>
<td>Post stent stenosis (%)</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>MLD (mm)</td>
<td>1.91</td>
<td>1.97</td>
</tr>
<tr>
<td>Diameter stenosis (%)</td>
<td>35</td>
<td>32</td>
</tr>
<tr>
<td>Binary restenosis rate</td>
<td>21</td>
<td>17</td>
</tr>
</tbody>
</table>

ACC B2/C indicates lesion morphology according to ACC/AHA Task Force Report, J Am Coll Cardiol. 1993;22:2033–2054; LAD, left anterior descending coronary artery; MLD, minimal luminal diameter; and binary restenosis rate, diameter stenosis >50% at follow-up.

*\( P<0.001 \) vs Palmaz-Schatz.
†\( P<0.05 \) vs Palmaz-Schatz.
§Graded by angiographic core laboratory.
"BElgian NEtherlands STENT study [BENESTENT]-like" lesions is predicated on showing similarity in safety and efficacy between the test stent and the Palmaz-Schatz stent, which serves as the standard with which all others are compared. These trials were not designed to test for subtle and perhaps clinically
Other issues that must be considered when evaluating a stent, other than equivalency to an arbitrary standard, are ease of use, versatility, and cost.

Custom-Designed Stents
With recent improvements in deployment techniques for intracoronary stents and increased operator experience, lesions previously considered not amenable to percutaneous treatment are now being treated with intracoronary stent implantation. Industry has responded to the demand with the production of myriad customized stents for very particular applications.

Bifurcation Lesions
Several new stent designs are available that are constructed specifically for use in bifurcation lesions. The Jostent B (Jomed International AB) is 1 such device. The configuration and size of the cells at 1 end of the Jostent B is similar to the first-generation Jostent M stent, with the cells connected with V-shaped bridges. At the other end of the stent, the cells are larger and connected with straight bridges (Figure 7A). On full expansion, the larger cells have a diameter of 3.5 mm, allowing easy access to the other arm of the vessel bifurcation.

CR Bard Inc is testing a true bifurcation stent. The Bard Bifurcation stent is shaped like a Y and is mounted on 2 balloons (Figure 7B). The main body of the stent is a single coil, through which the 2 balloons pass. The balloons diverge at the crux of the Y to pass separately through the 2 arms. Implantation into animals is currently under way, and the first human implants are being planned.

Side Branch
Stents specifically designed for use in the treatment of lesions at the site of significant side branches are also available. SciMed Life Systems supplies the NIRSide, which has the same basic design as the standard family of NIR stents; however, the cells in the center of the stent are larger than those at the ends. When properly positioned, the number of obstructing struts over the entrance to the side branch is...
minimized and side-branch access is facilitated. The design concept of the Jostent S (Jomed International AB) is similar to that of the NIRSide stent (Figure 7C).

Ostial Lesions
Devon Medical produces a stent designed exclusively for use in ostial lesions. The base design for the stent is the Pura-Vario A. At 1 end of the stent, however, the terminal row of cells is slightly longer and the struts slightly thicker (Figure 7D). This not only increases the radial force of this portion of the stent but also increases its radiopacity, which facilitates precise positioning.

Aneurysms or Perforations
The Jostent Coronary Stent Graft (Jomed International AB) is a unique integration of graft material into a coronary stent. This device was constructed with a sandwich technique whereby an ultrathin layer of expandable PTFE, specially developed for integration into a stent graft system, is placed between 2 stents with reduced strut thickness (Figure 7E). The Stent Graft is also offered coated with the Corline Heparin Surface, which has the potential to reduce the risk of thrombus formation after stent implantation.

A novel approach to stent customization for the treatment of vessel rupture and aneurysms has been developed by Drs Stefanadis and Toutouzas. Their approach involves passivation of the stent surface through the application of a segment of autologous vascular tissue. The technique uses a segment of cephalic vein or ulnar artery to cover the stent. The results of implantation of a device with a vein graft segment of cephalic vein or ulnar artery to cover the stent. The technique uses a segment of cephalic vein or ulnar artery to cover the stent.

Radioactive Stents
The use of stents as platform for the delivery of radiation to the vessel wall has been receiving considerable attention. Stent-bound radioactive sources can deliver effective doses of radioactivity to all levels of the vessel wall. It is also believed that radioactive stents can act by culling the smooth muscle cell population as these cells pass through the “electron fence” at the plane of the stent wires.

Hehrlein and colleagues were the first to describe the use of radioactive stents, which they implanted in nondiseased rabbit iliac arteries. The stainless steel stents were made radioactive by ion bombardment in a cyclotron and emitted both γ- and β-radiation from the radioisotopes 55,56,57 Co, 52 Mg, and 55 Fe. Stents with activities of 3.9, 17.5, and 35 mCi were tested. At 4 weeks, exposure to the 2 higher dose levels resulted in a significant reduction in neointimal formation, and all treated animals exhibited a significant reduction in neointimal thickening compared with nonradioactive stented controls. Further studies are necessary to clarify endothelial cell coverage was delayed in a dose-dependent manner.

Laird et al also examined the effects of a radioactive coil stent. They first ion-implanted the nonradioactive element 31 P beneath the surface of the stent. The stents were then made radioactive by exposure to neutron irradiation, which converts a fraction of the 31 P atoms to 32 P, a pure β-particle emitter. This technique results in an even distribution of 32 P within the stent, which ensures homogeneous distribution of β-particle irradiation from the stent. This technique, however, generates other short-lived radioisotopes. Intraluminal exposure for 28 days to these radioactive stents, with an initial activity of 0.014 mCi, caused a significant reduction in neointimal area and percent area stenosis compared with the effects of nonradioactive stents.

The efficacy of a relatively low-dose, pure β-emitting stent for the inhibition of intimal hyperplasia was first demonstrated by Hehrlein and colleagues. 32 P, produced by neutron bombardment, was ionized and ion-implanted beneath the outer surface of titanium-nickel stents. 32 P has several characteristics. 32 P-emitting stents with activities of 4 and 13 mCi were implanted in rabbit iliac arteries, and histomorphometry was performed at 4 and 12 weeks. At 4 weeks, both groups showed significant reductions in neointimal formation, whereas at 12 weeks, only the group receiving the highest radiation dose showed a significant reduction in neointima compared with nonradioactive stents.

With a similar radioactive stent, the neointimal responses to implantation in a porcine coronary restenosis model were examined in stents with activities from 0.15 to 23 mCi. Neointimal formation was seen to be reduced 28 days after the implantation of low-activity (0.15 to 0.5 mCi) and high-activity (3 to 23 mCi) stents, but increased neointimal formation was observed with stents of 1-mCi initial activity. These results highlight the complexity of the response of the vascular wall to ionizing radiations. The stent used in this trial has subsequently become known as the Fischell IsoStent (IsoStent/Cordis Corp, a Johnson & Johnson Interventional Systems Co). It is a stainless steel Palmaz-Schatz stent that has been modified to be β-particle-emitting by ion implantation as described above. Prompted by the encouraging results of β-particle-emitting stents on neointimal hyperplasia in animal models, a multicenter pilot study examining the feasibility and safety of the implantation of 1-mCi Palmaz-Schatz stents has been completed, and the larger randomized ISOStent for Restenosis Intervention Study (IRIS) trial is under way.

Proton activation of nitinol produces the predominantly β-emitting isotope 48 V. The Act-One stent (Progressive Angioplasty Systems Inc), the predecessor of the Paragon stent, has been made radioactive through proton activation and tested in pig coronary arteries. Radioactive Act-One stents with 1.5 mCi of 48 V activity had no effect on lumen narrowing or vessel histology, whereas 10-mCi 48 V stents inhibited neointimal thickening compared with nonradioactive stented control segments. Further studies are necessary to assess the effectiveness of radioactive nitinol stents for the prevention of restenosis.
TABLE 7. Coating Material Considered for Use With Metal Intracoronary Stents

<table>
<thead>
<tr>
<th>Synthetic Substances</th>
<th>Naturally Occurring Substances</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyurethane</td>
<td>Collagen/ laminin</td>
</tr>
<tr>
<td>Segmented polyurethane/heparin</td>
<td>Heparin</td>
</tr>
<tr>
<td>Poly-L-lactic acid</td>
<td>Fibrin</td>
</tr>
<tr>
<td>Cellulose ester</td>
<td>Phosphorylcholine</td>
</tr>
<tr>
<td>Polyethylene glycol</td>
<td>AZ1 adsorbed to cellulose</td>
</tr>
<tr>
<td>Polyphosphate ester</td>
<td>AZ1/UK adsorbed to cellulose</td>
</tr>
</tbody>
</table>

AZ1 indicates monoclonal antibody directed against rabbit platelet integrin αbβ3; AZ1/UK, monoclonal antibody directed against rabbit platelet integrin αbβ3/urokinase conjugate.

Stent Coatings

The list of materials used to coat metal stents in an attempt to reduce their inherent thrombogenicity and decrease the incidence of in-stent restenosis is long and ever increasing. The application of promising results in vitro and in vivo in animal models has led to the evaluation of the efficacy of these coatings in clinical trials. Many more animal data must be collected before this type of technology can be considered for clinical application.

As a result of their long residence times, attention has become focused on endovascular stents as a reservoir for prolonged local drug administration for the prevention of restenosis. This can be done by coating metallic stents with controlled-release matrices or incorporating a pharmacologically active compound into a polymeric stent or a polymer-metal composite stent.

Drug-polymer composites are referred to as monolithic matrices. When nondegradable matrices are used, drugs are delivered through sustained release by way of particle dissolution and diffusion through the cavitating network of the matrix. Extended drug release is possible through this approach, with formulations with release duration from hours to decades having been reported. Biodegradable polymer systems have also been used to formulate drug-delivery matrices. Biodegradable polymer matrices provide sustained delivery of pharmacological agents both by drug dissolution and by matrix degradation in vivo, leading to release of entrapped agents. The coating of a pharmaceutical stent with a biodegradable polymer also offers the attractive possibility that the drug-polymer system could disappear after a desired period of drug release.

Several candidate drugs for stent coatings have been considered. Undergoing clinical assessment is an InFlow
stent (InFlow Dynamics AG) coated with a poly lactic acid carrier containing 5% polyethylene-glycol-hirudin and 1% prostaglandin I2 analog (Iloprost). In vitro analysis demonstrated favorable degradation properties of the carrier and time-release characteristics of the incorporated antithrombotic and platelet-inhibiting drugs. Analysis of the hirudin- and Iloprost-eluting stents tested during stasis in a human shunt model demonstrated a significant effect on both platelet activation and blood coagulation, and when implanted in sheep coronary arteries, they have been shown to exhibit a favorable effect on neointimal formation. Another carrier/active agent system that appears promising is a cellulose polymer with passively adsorbed glycoprotein IIb/IIa receptor antibody. Active compound elutes from the stents in an exponential manner, with 48% of the bound agent eluted at 12 days when studied in vitro. When investigated in a rabbit iliac artery model, antibody to glycoprotein IIb/IIa eluted from cellulose-polymer–coated stents significantly reduced platelet aggregation in the stent microenvironment, reduced thrombus formation, improved blood flow and arterial patency rates, and inhibited cyclic blood flow variation.

The use of gene therapy in conjunction with a pharmaceutical delivery stent could involve the transfer of a desired gene from the stent coating to the cells of the arterial wall. This should result in the expression and synthesis of a desirable product by the cells of the arterial wall. This approach would involve the incorporation of DNA or a viral vector into a polymeric matrix system under conditions that would facilitate cellular uptake and translation of the DNA. Another important possible strategy for a pharmaceutical stent approach might involve the incorporation of antisense oligonucleotides into an appropriate polymeric matrix.

Interest in the development of a suitable biodegradable stent with pharmacologically active agents incorporated into the polymeric matrix, once a very active area of research, has waned considerably. To be effective, a drug-releasing biodegradable stent must be biocompatible, it must not cause an inflammatory reaction, and the breakdown products must be nontoxic. One such biodegradable device, however, that warrants mention is the Duke Biodegradable Stent, which is made from a special form of poly-t-lactide capable of incorporating pharmacologically active agents. Both self-expanding and balloon-expandable versions of the Duke stent have been designed and tested in animals with promising results.

The seeding of intravascular stents with endothelial cells to passivate the stent surface has been an area of ongoing research for >9 years. Both self-expanding and balloon-expandable stents have been successfully seeded with endothelial cells and have been shown to retain a significant number of viable cells after deployment in vivo. Using autologous endothelial cells derived from sheep saphenous veins, a group at the National Heart, Lung, and Blood Institute (NHBLI) has successfully seeded metallic stents and implanted the stents into the femoral arteries of the donor animals. The transplanted endothelial cells could be detected in 6 of 9 animals treated in this manner 10 days after stent implantation. Scott and colleagues also were successful in identifying endothelial cells on seeded stents 3 hours after intracoronary implantation in pigs. These investigators used immortalized human microvascular cells that retain the phenotypic characteristics of endothelial cells after >50 passages. The relevance of continued investment into the development of endothelium-covered stents may lie in the future possibility of seeding the stents with genetically modified endothelial cells capable of producing compounds for the treatment of restenosis.

Future Advances

Despite the phenomenal pace of stent design technology, the incidence of stent restenosis remains unacceptably high. To address this problem, intense investigation into new stent coatings continues, with new biocompatible and drug-eluting polymers being developed for application to the metal stent scaffold. As novel biocompatible drug delivery stent coatings are developed, pharmacological compounds that failed to prevent restenosis when administered systemically and those with significant systemic toxicity are now being reexamined. The new drug-eluting stents also provide a unique platform for the administration of proteinaceous compounds, antisense oligonucleotides, and DNA that cannot be given systemically. In addition, metal stents provide a convenient means for the application of brachytherapy by use of ionizing radiation. Although initial clinical results seem promising, issues of correct dosimetry and the long-term effects of cytotoxic therapies on the arterial wall have arisen. Despite recent significant strides in stent design technology, it is apparent that much has yet to be learned and further advances are necessary to improve the long-term outcome of patients treated with intravascular stents.

Angiogenesis and Transmyocardial Revascularization

Perhaps the most intriguing and exciting frontier in interventional cardiology is the ability to induce the growth of new blood vessels, a radically different therapeutic orientation compared with bypassing or deblocking diseased arteries. Several approaches have undergone pilot studies and have entered clinical trials involving either local angiogenic polypeptide growth factor administration, transfection of angiogenic genes, or the development of small channels in the endocardium to promote the passage of blood from the left ventricular cavity into the myocardium. The principal mechanism of improved myocardial blood flow for the latter approach, known as transmyocardial revascularization, is most likely related to stimulating angiogenesis, because the holes created by the laser (or other means) become fibrotic and occlude within weeks after the procedure.

Therapeutic angiogenesis is undergoing intensive early clinical investigation. Isner et al transfected the peripheral arteries with the cDNA for VEGF via a hydrogel-coated balloon catheter. This was successful in a few patients for improving peripheral arterial ischemia and served as proof of concept; then the same group initiated intramuscular injection of the VEGF naked human plasmid cDNA in 9 patients (10 ischemic limbs). In this initial series of intramuscular (rather than intra-arterial) injection of an angiogenic gene, 8 of 10 limbs had improved blood flow demonstrated...
by MRI, and there was an overall 30% increase in the ankle-brachial index, a key measure of ameliorated limb blood supply. Patients were excluded for any known malignancy, diabetic retinopathy, or other conditions that might be associated with untoward sequelae from “inappropriate” angiogenesis.

More recently, the initial forays into coronary angiogenesis have been reported. Schumacher et al.173 from Freiburg, Germany, published the results of a randomized trial of 40 patients who had intramyocardial injection of acidic fibroblast growth factor (FGF-1) into the distal anterior wall at the time of internal mammary artery bypass graft surgery. Within 12 weeks, the 20 patients randomized to active FGF-1 had digital angiographic evidence of neovascularization.173 During 3 years of follow-up, the ejection fraction improved from 50.3% to 63.8% in the treated group compared with 51.5% to 59.4% in the control (heat-inactivated FGF-1) group. No accelerated atherosclerosis or other untoward events were found.

In a parallel clinical investigation, intramyocardial injection of the gene for VEGF121 was initiated using an adenoviral vector at the time of bypass surgery.174 Like the clinical studies of Shumacher and colleagues, there was evidence from this preclinical porcine model of Mack et al.175 of extensive neovascularization at 4 weeks after VEGF transfection.

Henry and colleagues176 presented their findings on intracoronary VEGF administration in a small dose-finding pilot trial of 15 patients, which showed marked improvement in perfusion in 7 patients (47%) by thallium scintigraphy and improved collateralization in 5 of 7 patients who underwent follow-up angiography. A larger follow-up study that combines intracoronary and subsequent intravenous VEGF has just been initiated. Laham and associates177 used epicardial microcapsules with basic fibroblast growth factor in 8 patients at the time of bypass surgery, 4 of whom had enhanced perfusion by nuclear scans and MRI.

It was not fully anticipated that a single injection of either angiogenic protein or gene would produce prolonged neovascularization. This raises the question as to whether there is upregulation of angiogenic factors or their receptors once the stimulus is initiated.178 The process of new blood vessel formation is such a complex and wellorchestrated series of events, requiring a multitude of growth factors and regulatory proteins, that it is probably naive to think that a 1-time application of a single growth factor will yield optimal angiogenesis. The gene transfer approach may be preferred over the protein with regard to potential for durability, but with the adenoviral vector, issues including gene regulation over time and the potential for induction of a host inflammatory response are poorly understood. The naked cDNA plasmid strategy, applied for the peripheral arterial insufficiency indication, is fraught with low efficiency of transfer and probably more transient gene expression.

Although the angiogenesis can be demonstrated by imaging modalities, it is uncertain whether it will lead to normalization of perfusion or complete mitigation of provokable ischemia. It remains to be seen whether the collateral supply will be enhanced for long-term follow-up, but the functional data provided by Schumacher’s group are, at the very least, encouraging. Still, the unknown effects of accelerating atherosclerosis or facilitation of a latent malignancy need to be carefully assessed. Notwithstanding these concerns, large-scale clinical investigation for coronary angiogenesis with either the protein or gene for specific growth factors is warranted.

Substantial clinical pilot studies of transluminal myocardial revascularization (TMR) have suggested the potential for relief of angina.179–185 Three clinical trials have been completed with TMR performed at the time of open-heart surgery. With the CO2 laser, 198 patients were randomized to TMR or initial medical therapy.186 Holmium laser was also the subject of a randomized trial that enrolled 162 patients.187 The results of these 2 trials are remarkably concordant with reduction of angina, improvement of functional status, and in select patients with ancillary nuclear imaging, improved perfusion. As summarized in Figure 8, these salutary effects were also associated with less need for repeat hospitalization and less antianginal medication. For example, in the study by Allen et al.,187 the need for cardiac hospitalization at 3 months was reduced from 43% in medically managed patients to 20% in the group treated with TMR. Thus, it appears that TMR is effective for reducing angina, but the mechanism is not fully elucidated. Because the holes occlude fairly quickly, over just a few weeks in postmortem studies and experimental models, the most likely explanation for the benefit is angiogenesis.168–170,188 However, neuronal dysfunction induced by the laser has been raised as a plausible explanation for some of the antianginal effect based on elegant experimental modeling that focused on reflexes to systemic hypotension with bradykinin applied directly to the epicardium after TMR.189 Recent mechanistic studies have verified improvement in dobutamine-induced angina threshold, myocardial blood flow by PET, and even on indices of ventricular repolarization.190–192 With regard to safety, there were some initial concerns regarding a high operative mortality in these series (in the 8% to 10% range), but more recent experience suggests that this may have been attributable to patient selection or an obligatory operator learning curve.

The encouraging results in the initial surgical trials have led to clinical investigation with the use of holmium or...
excimer laser via the percutaneous approach. To date, no randomized trial data are available, but pilot studies demonstrate feasibility and apparent safety in the first few hundred patients treated. Clearly, the ability to direct the laser to the ischemic myocardial bed is lessened with the percutaneous approach, but new catheter-based sensor systems that are nonfluoroscopic and use electroanatomic mapping are being investigated to improve on the precision of where the holes are applied. Because the dominant mechanism may relate to stimulation of angiogenesis, it is not clear that precision is vital. The damage to the myocardium that is anticipated in the form of non–ST-elevation MI and its long-term effects has not been amply studied. A percutaneous strategy has obvious advantages, because it will allow more ready application to patients who are truly inoperable or can be used as an adjunct in patients with a chronic total occlusion that is not amenable to a routine epicardial strategy. Nevertheless, TMR will need considerable study and comparison with pharmacological or genetic forms of angiogenesis. Even the concept of injected angiogenic factors at the time the holes are created has been subjected to experimental study and, if shown clinically to be synergistic, may someday prove to be a useful combined strategy.

Another highly provocative strategy is a tissue-engineered blood vessel. L’Heureux and associates, in Quebec, have demonstrated the feasibility of cloning new arteries via cultured human smooth muscle cells, endothelial cells, and fibroblasts. Although this seems futuristic, it is possible that larger, bioengineered vessels cloned from patients who have significant ischemia may be a viable alternative in the next millennium to the conventional epicardial or emerging angiogenesis interventions of today.

Overall Perspective
The field of interventional cardiology is poised to go through significant further development. By the start of the 2000s, improved platelet coverage will be routine in all patients undergoing procedures, and oral therapies for more extended periods during follow-up will be more thoroughly investigated. It would not be at all surprising if angiogenesis therapy, be it by intracoronary, intramyocardial (at the time of surgery), or transmyocardial laser revascularization, became an important adjunctive means of achieving improved myocardial blood flow. Restenosis therapies will undoubtedly blossom beyond the initial application of radiation for in-stent restenosis, ideally taking advantage of the increased understanding that we now have of genetic control of cell proliferation and matrix production. Although stents are already being used in >60% of patients at the time of interventional procedures, their use will also increase further with improved designs, coatings, and the newfound ability to use the stent as an effective drug delivery station.

References
1816 Frontiers in Interventional Cardiology


71. Topol and Serruys October 27, 1998 1817


81. Topol and Serruys October 27, 1998 1817


92. Topol and Serruys October 27, 1998 1817


Frontiers in Interventional Cardiology


**KEY WORDS:** revascularization ■ stents ■ platelets ■ restenosis ■ angiogenesis
Frontiers in Interventional Cardiology
Eric J. Topol and Patrick W. Serruys

Circulation. 1998;98:1802-1820
doi: 10.1161/01.CIR.98.17.1802
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1998 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/98/17/1802

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/